Phase 3
N=301
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Glabellar Frown Lines
Bottom Line
View on ClinicalTrials.gov: NCT03960957 ↗Enrolled (actual)
301
Serious AEs
1.3%
Results posted
May 2021
Primary outcome: Primary: Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo — 142; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- AbobotulinumtoxinA (Biological); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Galderma R&D
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo |
142; 0 | — |
Summary
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Eligibility Criteria
Inclusion Criteria
- Moderate to severe glabellar lines at maximum frown
- Understands the study requirements and signs an informed consent form
Exclusion Criteria
- Botulinum toxin treatment in the face within 6 months prior to study treatment
Data sourced from ClinicalTrials.gov (NCT03960957). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.